StemBioSys expanding product portfolio and talent pipeline

The SA company has high hopes for its newest commercial opportunity

San Antonio-based StemBioSys Inc. is expanding its product portfolio and its core research talent.
The company, which is pursuing a range of commercial applications for its cell-based technology, is targeting a product roll out directed at researchers in the neuronal, or nerve, space.

The centerpiece of StemBioSys' technology is CELLvo Matrix, a cell-derived microenvironment that allows a variety of cells to replicate more rapidly. The new product, Neuro Matrix, will involve neuronal cells and is expected to assist researchers working in multiple disease areas.

"We recognized that there was a big unmet need for providing a better way for growing neuronal cells for research," StemBioSys CEO Bob Hutchens said. "This matrix supports growth of a broad range of neuronal cells. There are applications in a range of neuronal diseases such as Alzheimer's and Parkinson's Disease."

StemBioSys has applied for a National Institutes of Health-funded grant for the new matrix product, which is plans to bring to market in early 2022. It's also secured more expertise to support that expanded commercialization, adding Dr. Jeanne Loring, professor emeritus of the Scripps Research Institute, to its Scientific Advisory Board. Loring is also the founding director of the Center for Regenerative Medicine at Scripps and of Aspen Neuroscience. Hutchens said Loring, a pioneer in stem cell research, has extraordinary research credentials and deep experience in an area where StemBioSys sees plenty of untapped potential.

"It will give us access to a whole new market and new set of researchers," Hutchens said. "We view this as a major growth area for the company. The early interest we have had from academic researchers ... is a clear sign that this could be really important for us."

Source: *https://www.bizjournals.com/sanantonio/news/2021/12/20/stembiosys-expanding-product-portfolio.html*

December 20th 2021